A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, double-blind, randomized, placebo-controlled, first-in-human trial
evaluating a single ascending dose (4-way crossover, Part A) and multiple ascending doses
(Part B) of CVL-354.